参考文献/References:
1 Zelefsky MJ,Fuks Z,Hunt M,et al,High-dose intensity modulated radiation therapy for prostate cance:early toxicity and biochemical outcome in 772 patients.Int J Radiat Oncol Biol Phys,2002,53(5):1111-1116.
2 Pouliot J,Bani-Hashemi A,Chen J,et al.Low-dose megavoltage cone-beam CT for radiation therapy.Int J Radiat Oncol Biol Phys,2005,61(2)1 238-241.
3 Brenner DJ,Martinez A A,Edmundson GK,et al.Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio),similar to late-responding normal tissue.Int J Radiat Oncol Biol Phys,2002,52(1):6-13.
4 Wang JZ,Li XA,Yu CX,et al.The low alpha/beta ratio for prostate cancer:what does the clinical outcome of HDR brachytherapytell us?.Int J Radiat Oncol Biol Phys,2003,57(4):1101-1108.
5 Fowler J.Chappell R,Ritter M.Is alpha/beta for prostate tumors really low?.Int J Radiat Oncol Biol Phys,2001,50(4):1021-1031.
6 Fowler JF,Ritter MA,Chappell RJ,et al.What hypofractionated protocols should be tested for prostate cancer?.Int J Radiat Oncol Biol Phys,2003,56(4):1093-1104.
7 Syed AM,Puthawala A,Sharma A,et al.High-dose-rate brachytherapy in the treatment of carcinoma of the prostate.Cancer Control,2001,8(6):511-521.
8 Mate TP,Gottesman JE,Hatton J,et al.High dose-rate afterloading 192Iridium prostate brachytherapy:feasibility report.Int J Radiat Oncol Biol Phys,1998,41(3):525-533.
9 申文江.前列腺癌粒子植入近距离治疗.现代临床医学生物工程学杂志,2002,8(5):327-331.
10 Shigehara K,Mizokami A,Komatsu K,et al.Four year clinical statistics of iridium-192 high dose rate brachytherapy.Int J Urol,2006,13(2):116-121.
11 殷蔚伯.近距离治疗.殷蔚伯,谷铣之.肿瘤放射治疗学.第3版,北京:中国协和医科大学出版社.2002,16-20.
12 Cosset JM,Haie-Meder C.Brachytherapy for prostate cancer:highdose rate or low-dose rate?.Cancer Radiother,2005,9(8):610-619.
相似文献/References:
[1]田琦,张丽花,蒋宁一.甲状腺癌131I治疗后合并骨髓增生异常综合征一例[J].国际放射医学核医学杂志,2016,40(3):235.[doi:10.3760/cma.j.issn.1673-4114.2016.03.014]
[2]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[3]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[6]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[7]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[8]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[9]刘辰,杨悦,张雪宁,等.MRI和1997年版Partin表对前列腺癌病理特征预测准确性的对比研究[J].国际放射医学核医学杂志,2015,39(2):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
Liu Chen,Yang Yue,Zhang Xuening,et al.Accuracy of MRI and 1997 edition of Partin tables in predicting the pathological features of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
[10]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[11]邢岩,赵晋华.放射性核素标记铃蟾肽在前列腺癌诊治中的研究进展[J].国际放射医学核医学杂志,2010,34(3):158.
XING Yan,ZHAO Jin-hua.Progress of radiolabelled bombesin in diagnosis and treatment of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):158.